Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026)
Anaptysbio's (ANAB) quarterly Depreciation & Amortization (CF) came in at $130000.0 in Q1 2026, down 10.96% YoY from $146000.0 in Q1 2025, and down 0.76% on a QoQ basis from $131000.0 in Q4 2025.
Powered by 
Analysis
Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $130000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 10.96% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $543000.0 (down 7.81% YoY) and the FY2025 annual result came in at $559000.0, down 7.76% from the prior year.
- Depreciation & Amortization (CF) eased to $130000.0 in Q1 2026, from $131000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $184000.0 in Q4 2022 to a low of $130000.0 in Q1 2026.
- A 5-year average of $154235.3 and a median of $158000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) grew 29.6% — and 2024, when it retreated 12.12%.
- Tracing ANAB's Depreciation & Amortization (CF) over 5 years: stood at $184000.0 in 2022, then declined by 10.33% to $165000.0 in 2023, then dropped by 12.12% to $145000.0 in 2024, then dropped by 9.66% to $131000.0 in 2025, then slipped by 0.76% to $130000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $130000.0 (Q1 2026), $131000.0 (Q4 2025), and $140000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | 130,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 163,000.00 |
| Mar 31, 2023 | 166,000.00 |
| Dec 31, 2022 | 184,000.00 |
| Sep 30, 2022 | 166,000.00 |
| Jun 30, 2022 | 163,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Sep 30, 2021 | 169,000.00 |
| Jun 30, 2021 | 160,000.00 |